Table 3. Clinical characteristics of NSCLC patients with PD-L1 expression using 22C3 pharmDx assay.
| Variable | PD-L1 negative (TPS<1%) | PD-L1 positive (TPS≥1%) | p-value |
|---|---|---|---|
| No. (%) | 91 (39.6) | 139 (60.4) | |
| Age, yr | 0.276 | ||
| <60 | 29 (32.2) | 37 (27.6) | |
| ≥60 | 61 (67.8) | 97 (72.4) | |
| Sex | 0.281 | ||
| Male | 52 (57.1) | 86 (61.9) | |
| Female | 39 (42.9) | 53 (38.1) | |
| Smoking history | 0.652 | ||
| Never smoker | 44 (48.4) | 62 (44.6) | |
| Ex-smoker | 18 (19.8) | 35 (25.2) | |
| Current smoker | 29 (31.9) | 42 (30.2) | |
| Smoking status | |||
| Never smoker | 44 (48.4) | 62 (44.6) | 0.336 |
| Ever smoker | 47 (51.6) | 77 (55.4) | |
| Histologic type | 0.001* | ||
| Adenocarcinoma | 84 (92.3) | 110 (79.1) | |
| Squamous cell carcinoma | 5 (5.5) | 27 (19.4) | |
| Others | 0 (0.0) | 2 (1.4) | |
| Unknown | 2 (2.2) | 0 (0) | |
| EGFR mutation | 0.156 | ||
| Wild | 61(67.0) | 103 (74.1) | |
| Mutant | 30 (33.0) | 36 (25.9) | |
| Stage | 0.017 | ||
| I | 13 (14.3) | 10 (7.2) | |
| II | 3 (3.3) | 6 (4.3) | |
| III | 7 (7.7) | 30 (21.6) | |
| IV | 68 (74.7) | 93 (66.9) | |
| Stage | 0.065 | ||
| I | 13 (14.3) | 10 (7.2) | |
| ≥II | 78 (85.7) | 129 (92.8) |
*Fisher's exact test.
NSCLC: non-small cell lung cancer; PD-L1: programmed death-ligand 1; EGFR: epidermal growth factor receptor.